Synthesis, anticancer activities and molecular docking studies of a novel class of 2-Phenyl-5,6,7,8-tetrahydroimidazo [1,2-b]pyridazine derivatives bearing sulfonamides - Université d'Orléans Accéder directement au contenu
Article Dans Une Revue Molecules Année : 2022

Synthesis, anticancer activities and molecular docking studies of a novel class of 2-Phenyl-5,6,7,8-tetrahydroimidazo [1,2-b]pyridazine derivatives bearing sulfonamides

Résumé

In the present study, new 2-phenyl-5,6,7,8-tetrahydroimidazo [1,2-b]pyridazines bearing sulfonamides were synthesized, characterized and evaluated for their anticancer activities. The structures of these derivatives were elucidated by 1H NMR, 13C NMR, infrared and high-resolution mass spectrometry for further validation of the target compound structures. The anticancer activities of the new molecules were evaluated against five human cancer cell lines, including A-549, Hs-683, MCF-7, SK-MEL-28 and B16-F10 cell lines using 5-fluorouracil and etoposide as the reference drugs. Among the tested compounds, 4e and 4f exhibited excellent activities in the same range of the positive controls, 5-fluorouracil and etoposide, against MCF-7 and SK-MEL-28 cancer cell lines, with IC50 values ranging from 1 to 10 μM. The molecular docking studies of 4e and 4f showed a strong binding with some kinases, which are linked to MCF-7 and SK-MEL-28 cancer cell lines.
Fichier principal
Vignette du fichier
molecules-27-05238.pdf (6.96 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03890842 , version 1 (13-12-2022)

Licence

Paternité

Identifiants

Citer

Otmane Bourzikat, Abdelmoula El Abbouchi, Hamza Ghammaz, Nabil El Brahmi, Elmostfa El Fahime, et al.. Synthesis, anticancer activities and molecular docking studies of a novel class of 2-Phenyl-5,6,7,8-tetrahydroimidazo [1,2-b]pyridazine derivatives bearing sulfonamides. Molecules, 2022, 27 (16), pp.5238. ⟨10.3390/molecules27165238⟩. ⟨hal-03890842⟩
61 Consultations
26 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More